Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Prepaid Assets (2019 - 2025)

BridgeBio Pharma's Prepaid Assets history spans 7 years, with the latest figure at $44.1 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 26.39% year-over-year to $44.1 million; the TTM value through Dec 2025 reached $44.1 million, up 26.39%, while the annual FY2025 figure was $44.1 million, 26.39% up from the prior year.
  • Prepaid Assets for Q4 2025 was $44.1 million at BridgeBio Pharma, down from $52.4 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $60.2 million in Q2 2025 and bottomed at $20.5 million in Q2 2023.
  • The 5-year median for Prepaid Assets is $30.2 million (2021), against an average of $32.3 million.
  • The largest annual shift saw Prepaid Assets crashed 37.27% in 2023 before it soared 112.14% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $32.3 million in 2021, then tumbled by 32.06% to $21.9 million in 2022, then increased by 10.87% to $24.3 million in 2023, then surged by 43.46% to $34.9 million in 2024, then rose by 26.39% to $44.1 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Prepaid Assets are $44.1 million (Q4 2025), $52.4 million (Q3 2025), and $60.2 million (Q2 2025).